Medicus Pharma Fireside Chat: Analyzing the SKNJCT-003 Phase 2 Trial Results and Stock Performance
Medicus Pharma Ltd. will be participating in a fireside chat on March 19, 2026, at 11:00 a.m. Eastern Time. The event, hosted by Senior Biotechnology Analyst Kumaraguru Raja, will feature Dr. Raza Bokhari, the company's Executive Chairman and CEO. They will discuss the results of the SkinJect SKNJCT-003 Phase 2 clinical trial, which evaluated microneedle-mediated delivery of doxorubicin for nodular basal cell carcinoma patients. The study showed promising results with the 200-microgram dose achieving 73% clinical clearance at Day 57 among patients.
Despite the positive clinical data, investors have shown caution, leading to a decline in the company's stock price. The stock currently trades at $0.50, down significantly over the past year. However, InvestingPro analysis suggests that the stock may be undervalued, with the company's Fair Value estimated to be higher than the current trading price. The company is set to report earnings on March 30.
Medicus Pharma is a biotech company focused on developing therapeutic assets for non-melanoma skin diseases and prostate cancer treatment. The company remains unprofitable but has received clearance from the FDA to commence a Phase 2b trial for Teverelix, a drug for advanced prostate cancer. The company has also amended its license agreement with LifeArc to retain exclusive global rights to Teverelix. Investors can access additional ProTips and financial metrics on the InvestingPro platform.
In conclusion, Medicus Pharma's participation in the fireside chat and the promising results of the SKNJCT-003 Phase 2 clinical trial highlight the company's commitment to developing innovative treatments for skin diseases and cancer. Despite challenges in the stock market, the company's potential for growth and success in advancing its clinical programs offer significant upside potential for investors.